stockrowPalisade Bio, Inc. (PALI) vs Protalix BioTherapeutics, Inc. (PLX)
- Palisade Bio, Inc. PALI 1.13 −2.59%
- Protalix BioTherapeutics, Inc. PLX 2.54 +1.20%
Palisade Bio, Inc. and Protalix BioTherapeutics, Inc. are both Biotechnology companies. Palisade Bio, Inc. and Protalix BioTherapeutics, Inc. are of similar size ($202.2M and $202.2M). Palisade Bio, Inc. trades at the lower P/E: 1.8× against 10.5×. Palisade Bio, Inc. grew revenue faster over the last twelve months: 5,492.6% against 30.1%. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs −4,230.6%) and the higher return on invested capital (48.5% vs 0.00%). Across the 18 metrics below, Palisade Bio, Inc. leads on 9 and Protalix BioTherapeutics, Inc. on 9.
Valuation
Profitability
| Metric | PALI | PLX | Biotechnology median |
|---|---|---|---|
| Gross margin | 95.63% | 69.20% | 68.51% |
| Operating margin | (4,681.99%) | 28.89% | 0.00% |
| Net margin | (4,230.60%) | 23.50% | 0.00% |
| Free cash flow margin | (2,409.27%) | 9.51% | 0.00% |
| Return on equity | (51.37%) | 31.23% | (51.96%) |
| Return on assets | (47.68%) | 20.07% | (46.06%) |
| Return on invested capital | 0.00% | 48.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack